||Fas ligand (FasL) is a type II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Fas ligand is a homotrimeric protein and signals through trimerization of FasR, which spans the membrane of the "target" cell. This trimerization usually leads to apoptosis, or cell death. Soluble Fas ligand is generated by cleaving membrane-bound FasL at a conserved cleavage site by the external serine matrix metalloproteinase MMP-7. Soluble FasL is less active than their membrane-bound counterparts and do not induce receptor trimerization and DISC formation. FasL is regarded as a potential target for immunotherapy.
||CD33 Signal Peptide+hhhhhhpspp pekkelrkva hltgksnsrs mplewedtyg ivllsgvkyk kgglvinetg lyfvyskvyf rgqscnnlpl shkvymrnsk ypqdlvmmeg kmmsycttgq mwarssylga vfnltsadhl yvnvselslv nfeesqtffg lykl.
||The predicted molecular weight of Recombinant Human FasL is 18 kDa. However, the actual molecular weight as observed on polyacrylimide gels is 26 - 28 kDa.
|State Of Matter:
||>95% by SDS Page.
||The biological activity of Human Soluble Fas Ligand is determined by its ability to induce cytotoxicity in Jurkat cells. The expected ED50 for this effect is <1.0 - 3.0 ng/ml, in the presence of 10 µg/ml of a cross-linking antibody.